Cognition Therapeutics Inc.’s stock tumbled 31% Monday to put it on track for its biggest-ever one-day percentage decline, after the company said a Phase 2 trial of an oral treatment for mild to ...

Two other analysts cut their firms’ 12-month price targets on Cognition stock: Raghuram Selvaraju chopped H.C. Wainwright’s target 30%, from $10 to $7, while Aydin Huseynov sliced Ladenburg ...

Cognition Therapeutics (NASDAQ:CGTX) shares jumped in premarket trade on Monday after a mid-stage trial showed consistent improvement in cognitive outcomes with its experimental once-daily oral ...

Cognition Therapeutics' stock price fell over 43% after the company shared results from its Phase II proof-of-concept SHINE (NCT03507790) trial that demonstrated lead candidate CT1812 failed to ...

Cognition's common stock began trading on the Nasdaq Global Market on October 8, 2021, under the ticker symbol "CGTX", priced at $12 per share. CGTX has traded in a range of $1.07 to $6.26 in the ...

Cognition also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock to be sold in the offering. The offering ...